ten23 health, the human-centric and sustainable strategic contract development, testing and manufacturing organization (CDTMO) partner of choice for the pharmaceutical industry and biotech start-ups, is proud to announce the establishment of its Advisory Board, bringing together leading global experts to confirm its commitment to a "Patients," "People," and "Planet" focused corporate social responsibility policy.
ten23 health has partnered with the St. Gallen Symposium and its Young Leaders on Boards initiative to appoint outstanding leaders to its newly established Advisory Board. Merging experience with innovation, intergenerational collaboration fosters a dynamic team, offering fresh perspectives, ideas, and benchmark standards to advance the company’s mission.
The newly appointed members of the board will provide support on different topics at ten23 health: Susan Hershenson and Aya Chebbi join to strengthen patient-centered initiatives; Jonas Friedrich will advise on people-focused efforts; while Donald Sandmann will spearhead sustainability initiatives centered on the planet. Their diverse expertise in advocacy, organizational structure, and sustainability will help shape ten23 health’s future.
“Adding diverse perspectives into organizational strategy is key to ensuring long-term and sustainable success and innovation,” explained Prof. Dr. Hanns-Christian Mahler, Chief Enablement Officer (CEO) of ten23 health. He added: “With the recent establishment of our Advisory Board, we can add important elements of intergenerational leadership and benefit from the insights and long-term thinking of both young and most experienced leaders, to drive further ideation and outcomes for our Patients, People and Planet agenda at ten23.”